What are the epidemiologic incidence rates and dose‑dependent side effects of modafinil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Modafinil Side Effects: Epidemiologic Incidence and Dose-Dependent Profile

Based on FDA data from over 3,500 patients in placebo-controlled trials, the most common adverse reactions (≥5%) are headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia, with only headache and anxiety demonstrating clear dose-dependent increases. 1

Common Side Effects with Incidence Rates

From the FDA label analyzing 934 modafinil-treated patients versus 567 placebo patients, the specific incidence rates are:

Most Frequent (≥5%):

  • Headache: Most common, dose-dependent
  • Nausea: 5% (vs 1% placebo)
  • Nervousness: 5% (vs 1% placebo)
  • Dizziness: 5% (vs 4% placebo)
  • Insomnia: 5% (vs 1% placebo)
  • Dyspepsia: 5% (vs 4% placebo)

Moderately Common (2-4%):

  • Anorexia: 4% (vs 1% placebo)
  • Dry mouth: 4% (vs 2% placebo)
  • Pharyngitis: 4% (vs 2% placebo)
  • Chest pain: 3% (vs 1% placebo)
  • Hypertension: 3% (vs 1% placebo)
  • Depression: 2% (vs 1% placebo)
  • Palpitations: 2% (vs 1% placebo)
  • Tachycardia: 2% (vs 1% placebo) 1

Dose-Dependent Effects

Critical finding: Only two adverse reactions showed clear dose-dependency in trials comparing 200,300, and 400 mg/day doses—headache and anxiety. 1 This is important because it means most side effects do not predictably increase with higher doses within the therapeutic range.

A 2026 meta-analysis across different conditions confirmed condition-specific patterns: OSA patients had the highest risk ratios for insomnia (RR: 5.82), anxiety (RR: 3.26), and headache (RR: 1.92), while narcolepsy patients showed elevated risks primarily for gastrointestinal effects like diarrhea (RR: 2.16) and nausea (RR: 2.44). 2

Discontinuation Rates

8% of patients discontinued modafinil due to adverse reactions versus 3% on placebo. The most frequent reasons for discontinuation were:

  • Headache: 2%
  • Nausea, anxiety, dizziness, insomnia, chest pain, nervousness: each <1% 1

Serious and Rare Adverse Events

Life-Threatening Reactions (Incidence <1%)

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): The reporting rate exceeds background incidence (1-2 cases per million-person years). In pediatric trials, rash requiring discontinuation occurred in 0.8% (13/1,585 patients), including 1 possible SJS case. Nearly all serious rashes occurred within 1-5 weeks of initiation, though isolated cases occurred after 3 months. 1

Multi-organ hypersensitivity reactions: Median time to detection is 13 days (range 4-33 days). These present with fever, rash, and organ involvement including myocarditis, hepatitis, eosinophilia, leukopenia, and thrombocytopenia. At least one fatality has been reported. 1

Psychiatric adverse events: A 2026 systematic review of 24 cases found modafinil-associated psychosis occurred at a median dose of 250 mg/day, with hallucinations (66.7%) and delusions (58.3%) being most common. Importantly, psychosis can occur even at therapeutic doses. 3

Cardiovascular events: Postmarketing surveillance identified stress cardiomyopathy, brain edema, and eosinophilic myocarditis as new signals not in the original labeling. 4

Hematologic: Agranulocytosis reported in postmarketing surveillance. 1

Pregnancy-Related Risks

A 2026 French nationwide cohort study (786 exposed pregnancies) found no increased risk of major congenital malformations (4.2% vs 3.3% unexposed, RR 1.32,95% CI 0.81-2.15). However, elective terminations were 32% more frequent (PR 1.32,95% CI 1.14-1.51), likely reflecting clinical decisions around maternal narcolepsy. 5 This contradicts earlier US registry data suggesting increased malformation risk, but the French study is larger and more recent.

Laboratory Abnormalities

Liver enzymes: Mean gamma glutamyltransferase (GGT) and alkaline phosphatase (AP) levels were elevated with modafinil versus placebo, with values increasing over time. However, few patients had elevations outside normal range. No differences in ALT, AST, total protein, albumin, or bilirubin. 1

Timing of Adverse Events

Most adverse events occur within the first month of treatment. Analysis of FAERS database showed median onset time of 76.5 days (IQR 14-392 days), but the highest concentration of cases occurred in the first 30 days. 4

Clinical Pitfalls and Caveats

Discontinue immediately at first sign of rash—you cannot reliably distinguish benign from life-threatening rashes, and waiting can result in permanent disability or death. 1

Higher doses (>200 mg) increase serious adverse event risk: In shift work disorder trials, serious adverse events were significantly higher at higher doses (Peto's OR 4.80,95% CI 1.18-19.56). 6 The 2021 AASM guideline notes that doses up to 400 mg/day are well-tolerated but provide no consistent additional benefit beyond 200 mg/day. 7

Psychiatric history increases risk: Exercise particular caution in patients with depression, schizophrenia, or other psychiatric conditions—these comprised 41.6% of psychosis cases in the systematic review. 3

Pediatric use carries black box warning for Stevens-Johnson syndrome and psychosis based on case reports, though modafinil is not FDA-approved for patients <17 years. 7

Pregnancy considerations: While the 2026 French study is reassuring, modafinil remains contraindicated in pregnancy per FDA guidance due to animal data showing fetal harm. Alternative contraception is required during treatment and for one month after discontinuation due to reduced oral contraceptive effectiveness. 7, 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.